BioMedNewsBreaks – RYAH Group Inc. Provides Digital Approach to Positively Impact Future Medical Treatments

RYAH Group, a leading digital health care analytics and technology company, has developed a technology that collects and analyzes patient data, creating an anonymous database that, when coupled with AI, will guide the future of medical treatments. With the technology, “patients can set usage limits, track usage in real time, record how they feel after sessions and review stats over time,” reads an article on the developments. “The patient controls the process, and the instruments that collect digital data remain anonymous. When patient feedback is optimized, medical trials and studies can move into remote solution zones… RYAH is focused on expanding the understanding of proprietary technology that supports a data-driven approach to positively impact patients’ future treatment for various medical conditions. By coupling an anonymous database with AI, the company has created a cloud of stored data to help with the R&D of future medical treatments. RYAH is actively making digital transformation in the lab a reality, paving the way forward for a medical future with remote solutions.”

To view the full article, visit https://ibn.fm/NdYmQ

RYAH Group Inc.

RYAH Group is a leader in digital health care analytics and technology. By creating a suite of dose-measuring, IoT devices that capture data from seed to consumption, RYAH is positioned to unearth breakthrough discoveries capable of reshaping the understanding of plant-based medicine. For more information, visit the company’s website at www.RYAHGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the company’s newsroom at https://ibn.fm/RYAH  

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) CEO Highlights 2026 Clinical Milestones and Strategic Options

Soligenix (NASDAQ: SNGX) issued a shareholder update from President and CEO Dr. Christopher J. Schaber outlining anticipated…

3 hours ago

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Expands Global Intellectual Property Portfolio Supporting OT-101 Across Neurology and CNS Delivery 

Oncotelic Therapeutics (OTCQB: OTLC) and Sapu Bioscience announced key advancements in their global intellectual property portfolio supporting OT-101, a…

3 hours ago

BioMedNewsBreaks – NanoViricides (NYSE American: NNVC) Files Orphan Drug Designation Application for NV-387 in MPox

NanoViricides, Inc. (NYSE American: NNVC) announced it has filed an application for Orphan Drug Designation…

5 hours ago

BioMedNewsBreaks — LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Bringing First-in-Class Approach to Chemo and Immunotherapy

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, is focused on enhancing established cancer…

23 hours ago

BioMedNewsBreaks – Earth Science Tech, Inc. (OTC: ETST) to Report Fourth-Quarter 2025 Financial Results Feb. 17

Earth Science Tech (OTC: ETST), a strategic holding company focused on acquiring and scaling high-potential…

2 days ago

BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Previews 2026 Milestones for Intranasal Concussion Therapeutic ONP-002

Oragenics (NYSE American: OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics using proprietary intranasal delivery…

3 days ago